Annual CFO
-$31.71 M
-$3.54 M-12.55%
December 31, 2023
Summary
- As of February 6, 2025, TRVI annual cash flow from operations is -$31.71 million, with the most recent change of -$3.54 million (-12.55%) on December 31, 2023.
- During the last 3 years, TRVI annual CFO has fallen by -$2.71 million (-9.34%).
- TRVI annual CFO is now -297.62% below its all-time high of -$7.97 million, reached on December 31, 2017.
Performance
TRVI Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$9.56 M
-$873.00 K-10.05%
September 30, 2024
Summary
- As of February 6, 2025, TRVI quarterly cash flow from operations is -$9.56 million, with the most recent change of -$873.00 thousand (-10.05%) on September 30, 2024.
- Over the past year, TRVI quarterly CFO has dropped by -$3.20 million (-50.28%).
- TRVI quarterly CFO is now -141.68% below its all-time high of -$3.95 million, reached on March 31, 2018.
Performance
TRVI Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$35.06 M
-$2.28 M-6.94%
September 30, 2024
Summary
- As of February 6, 2025, TRVI TTM cash flow from operations is -$35.06 million, with the most recent change of -$2.28 million (-6.94%) on September 30, 2024.
- Over the past year, TRVI TTM CFO has dropped by -$3.35 million (-10.58%).
- TRVI TTM CFO is now -786.82% below its all-time high of -$3.95 million, reached on March 31, 2018.
Performance
TRVI TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
TRVI Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -12.6% | -50.3% | -10.6% |
| 3 y3 years | -9.3% | -32.0% | -10.8% |
| 5 y5 years | -73.4% | -23.6% | -51.8% |
TRVI Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -12.6% | at low | -54.7% | +8.7% | -31.1% | at low |
| 5 y | 5-year | -37.3% | at low | -104.5% | +8.7% | -51.8% | at low |
| alltime | all time | -297.6% | at low | -141.7% | +8.7% | -786.8% | at low |
Trevi Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$9.56 M(+10.1%) | -$35.06 M(+6.9%) |
| Jun 2024 | - | -$8.68 M(-17.0%) | -$32.79 M(-3.5%) |
| Mar 2024 | - | -$10.47 M(+64.6%) | -$33.98 M(+7.2%) |
| Dec 2023 | -$31.71 M(+12.5%) | -$6.36 M(-12.6%) | -$31.71 M(+0.1%) |
| Sep 2023 | - | -$7.28 M(-26.3%) | -$31.68 M(-3.9%) |
| Jun 2023 | - | -$9.88 M(+20.5%) | -$32.98 M(+12.6%) |
| Mar 2023 | - | -$8.20 M(+29.5%) | -$29.28 M(+3.9%) |
| Dec 2022 | -$28.18 M(-2.7%) | -$6.33 M(-26.2%) | -$28.18 M(+0.4%) |
| Sep 2022 | - | -$8.58 M(+38.9%) | -$28.07 M(+5.0%) |
| Jun 2022 | - | -$6.18 M(-12.9%) | -$26.74 M(-6.1%) |
| Mar 2022 | - | -$7.09 M(+13.9%) | -$28.46 M(-1.7%) |
| Dec 2021 | -$28.95 M | -$6.23 M(-14.0%) | -$28.95 M(-8.5%) |
| Sep 2021 | - | -$7.24 M(-8.3%) | -$31.64 M(+0.9%) |
| Jun 2021 | - | -$7.90 M(+4.2%) | -$31.37 M(-1.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$7.58 M(-15.1%) | -$31.91 M(+10.0%) |
| Dec 2020 | -$29.00 M(+25.6%) | -$8.92 M(+28.1%) | -$29.00 M(+10.4%) |
| Sep 2020 | - | -$6.97 M(-17.4%) | -$26.28 M(-2.8%) |
| Jun 2020 | - | -$8.44 M(+80.5%) | -$27.05 M(+14.3%) |
| Mar 2020 | - | -$4.67 M(-24.7%) | -$23.67 M(+2.5%) |
| Dec 2019 | -$23.09 M(+26.3%) | -$6.20 M(-19.8%) | -$23.09 M(+6.8%) |
| Sep 2019 | - | -$7.73 M(+52.8%) | -$21.62 M(+20.9%) |
| Jun 2019 | - | -$5.06 M(+23.6%) | -$17.88 M(-3.0%) |
| Mar 2019 | - | -$4.10 M(-13.4%) | -$18.43 M(+0.8%) |
| Dec 2018 | -$18.29 M(+129.3%) | -$4.73 M(+18.5%) | -$18.29 M(+34.9%) |
| Sep 2018 | - | -$3.99 M(-28.8%) | -$13.56 M(+41.8%) |
| Jun 2018 | - | -$5.61 M(+41.9%) | -$9.56 M(+141.9%) |
| Mar 2018 | - | -$3.95 M | -$3.95 M |
| Dec 2017 | -$7.97 M | - | - |
FAQ
- What is Trevi Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Trevi Therapeutics?
- What is Trevi Therapeutics annual CFO year-on-year change?
- What is Trevi Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Trevi Therapeutics?
- What is Trevi Therapeutics quarterly CFO year-on-year change?
- What is Trevi Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Trevi Therapeutics?
- What is Trevi Therapeutics TTM CFO year-on-year change?
What is Trevi Therapeutics annual cash flow from operations?
The current annual CFO of TRVI is -$31.71 M
What is the all time high annual CFO for Trevi Therapeutics?
Trevi Therapeutics all-time high annual cash flow from operations is -$7.97 M
What is Trevi Therapeutics annual CFO year-on-year change?
Over the past year, TRVI annual cash flow from operations has changed by -$3.54 M (-12.55%)
What is Trevi Therapeutics quarterly cash flow from operations?
The current quarterly CFO of TRVI is -$9.56 M
What is the all time high quarterly CFO for Trevi Therapeutics?
Trevi Therapeutics all-time high quarterly cash flow from operations is -$3.95 M
What is Trevi Therapeutics quarterly CFO year-on-year change?
Over the past year, TRVI quarterly cash flow from operations has changed by -$3.20 M (-50.28%)
What is Trevi Therapeutics TTM cash flow from operations?
The current TTM CFO of TRVI is -$35.06 M
What is the all time high TTM CFO for Trevi Therapeutics?
Trevi Therapeutics all-time high TTM cash flow from operations is -$3.95 M
What is Trevi Therapeutics TTM CFO year-on-year change?
Over the past year, TRVI TTM cash flow from operations has changed by -$3.35 M (-10.58%)